Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Connect Biopharma Holdings Ltd has a consensus price target of $6.67 based on the ratings of 3 analysts. The high is $8 issued by HC Wainwright & Co. on April 1, 2025. The low is $5 issued by Cantor Fitzgerald on September 13, 2023. The 3 most-recent analyst ratings were released by HC Wainwright & Co. on April 1, 2025, March 31, 2025, and September 6, 2024, respectively. With an average price target of $8 between HC Wainwright & Co., there's an implied 889.94% upside for Connect Biopharma Holdings Ltd from these most-recent analyst ratings.
1calculated from analyst ratings
Buy Now | Get Alert | |||||||
---|---|---|---|---|---|---|---|---|
04/01/2025 | Buy Now | 889.94% | HC Wainwright & Co. | Emily Bodnar37% | $8 → $8 | Reiterates | Buy → Buy | Get Alert |
03/31/2025 | Buy Now | 889.94% | HC Wainwright & Co. | Emily Bodnar37% | $8 → $8 | Reiterates | Buy → Buy | Get Alert |
09/06/2024 | Buy Now | 889.94% | HC Wainwright & Co. | Emily Bodnar37% | $8 → $8 | Reiterates | Buy → Buy | Get Alert |
06/13/2024 | Buy Now | 889.94% | HC Wainwright & Co. | Emily Bodnar37% | $8 → $8 | Reiterates | Buy → Buy | Get Alert |
04/17/2024 | Buy Now | 889.94% | HC Wainwright & Co. | Emily Bodnar37% | $7 → $8 | Maintains | Buy | Get Alert |
03/04/2024 | Buy Now | 766.2% | HC Wainwright & Co. | Emily Bodnar37% | → $7 | Initiates | → Buy | Get Alert |
09/13/2023 | Buy Now | 518.71% | Cantor Fitzgerald | Louise Chen51% | → $5 | Reiterates | Overweight → Overweight | Get Alert |
02/08/2023 | Buy Now | 766.2% | SVB Leerink | Thomas Smith33% | $9 → $7 | Maintains | Outperform | Get Alert |
06/02/2022 | Buy Now | 518.71% | Cantor Fitzgerald | Louise Chen51% | → $5 | Initiates | → Overweight | Get Alert |
The latest price target for Connect Biopharma Hldgs (NASDAQ:CNTB) was reported by HC Wainwright & Co. on April 1, 2025. The analyst firm set a price target for $8.00 expecting CNTB to rise to within 12 months (a possible 889.94% upside). 4 analyst firms have reported ratings in the last year.
The latest analyst rating for Connect Biopharma Hldgs (NASDAQ:CNTB) was provided by HC Wainwright & Co., and Connect Biopharma Hldgs reiterated their buy rating.
There is no last upgrade for Connect Biopharma Hldgs
There is no last downgrade for Connect Biopharma Hldgs.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Connect Biopharma Hldgs, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Connect Biopharma Hldgs was filed on April 1, 2025 so you should expect the next rating to be made available sometime around April 1, 2026.
While ratings are subjective and will change, the latest Connect Biopharma Hldgs (CNTB) rating was a reiterated with a price target of $8.00 to $8.00. The current price Connect Biopharma Hldgs (CNTB) is trading at is $0.81, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
A newsletter built for market enthusiasts by market enthusiasts. Top stories, top movers, and trade ideas delivered to your inbox every weekday before and after the market closes.